Introduction {#s1}
============

*Klebsiella pneumoniae* are ubiquitous in nature and have two common habitats; one is the environment, including surface water, sewage, soils and plants [@pone.0061428-Kumar1], and the other is mammalian mucosal surfaces [@pone.0061428-Brisse1]. In humans, *K. pneumoniae* can be present in the intestinal tract, nasopharynx, and on the skin [@pone.0061428-EARSNet1]. It is one of the most common Gram-negative bacteria encountered by clinicians worldwide as a cause of infections in humans [@pone.0061428-Khan1] and is responsible for outbreaks due to the propagation of different clones associated with opportunistic infections in individuals with impaired immune defenses, such as diabetics, alcoholics and hospitalized patients with indwelling devices [@pone.0061428-EARSNet1]. In the hospital environment, the principal reservoirs for *K. pneumoniae* transmission are blood products, contaminated medical equipment, the gastrointestinal and respiratory tracts of patients and the hands of hospital personnel [@pone.0061428-Podschun1]. The hospital-acquired infections caused by this organism mainly include pneumonia, septicemia, urinary tract infections and soft tissue infections [@pone.0061428-Decre1].

Increased *K. pneumoniae* infections are also associated with an increase in multidrug-resistant (MDR) strains, especially those producing extended-spectrum beta-lactamases (ESBLs) [@pone.0061428-Turner1] associated with the prior use of antibiotics, particularly the cephalosporins [@pone.0061428-MosquedaGomez1]. Furthermore, several carbapenemase-encoding genes have been described in *K. pneumoniae* species, including class A beta-lactamase KPC, class B beta-lactamases NDM, IMP and VIM, and class D beta-lactamase OXA-48 [@pone.0061428-Nordmann1]. The hospital epidemiology of these infections is often complex because multiple clonal strains causing focal outbreaks may co-exist with sporadic strains that also have a reservoir in the community [@pone.0061428-Falagas1]. Infections caused by multidrug-resistant *K. pneumoniae* strains have been associated with adverse clinical outcomes, including increased mortality, prolonged hospital stays and increased economic costs [@pone.0061428-Schwaber1].

Therefore, epidemiological typing is useful in determining the extent of an outbreak and in investigating the sources, the reservoir and the spread of bacterial infections. Various methods, including protein profiling by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and DNA profiling by multilocus sequence typing (MLST), restriction fragment length polymorphism (RFLP) and pulsed field gel electrophoresis (PFGE), have been used for the epidemiological typing of *K. pneumoniae* isolates [@pone.0061428-Malik1]--[@pone.0061428-Siu1]. However, most of these methodologies are time consuming, laborious, require special skills and are unsuitable for use in routine clinical laboratories [@pone.0061428-Baker1], [@pone.0061428-Barbuddhe1]. In recent years, several reports have shown the feasibility of using matrix-assisted laser desorption ionization (MALDI)-time of flight (TOF) mass spectrometry (MS) to rapidly identify microorganisms [@pone.0061428-Sauer1]. There are only a few studies that have evaluated this method as a rapid tool to classify bacterial species at the strain level [@pone.0061428-Seng1], [@pone.0061428-Murray1]. However, there are some recent examples of the use of MALDI-TOF MS for the rapid identification and typing of a limited number of clinical strains, such as *Streptococcus pyogenes* [@pone.0061428-Wang1] or *Klebsiella pneumoniae* [@pone.0061428-Murray1].

Here, we report the evaluation of MALDI-TOF MS as a rapid and powerful tool for determining the epidemiological distribution of a large series of *K. pneumoniae* clinical strains of different origins from patients with various infectious syndromes and the correlation between the pathotypes, geographic locations and clonalities of these strains using MALDI-TOF MS and data-mining approaches.

Results {#s2}
=======

Clinical Data {#s2a}
-------------

The mean age of the infected patients was 53 years and was similar when comparing patients hospitalized in Algerian hospitals (53 years: range 12 days to 84 years) and those from French hospitals (53.1 years: range 1 day to 97 years). The male/female ratio was 1/1. Among the 535 isolates, 172 (32.1%) were retrieved from intensive care units (ICUs), 160 (29.9%) from infectious diseases wards, 40 (7.5%) from surgical wards, 38 (7.1%) from emergency wards, 22 (4.1%) from pediatric wards, 21 (3.9%) from trauma wards, 21 (3.9%) from neurology wards, 16 (3.0%) from internal medicine wards, 14 (2.6%) from nephrology wards, 14 (2.6%) from gastroenterology wards, and 17 (3.2%) from gynecology, cardiology, or geriatric medicine wards. *K. pneumoniae* strains were isolated from various clinical samples that originated as follows: 189 (35.3%) from urine, 113 (21.1%) from tracheal aspirate, 73 (13.6%) from pus, 67 (12.5%) from blood culture, 36 (6.7%) from rectal swab and 57 (10.6%) from other different clinical specimens.

Bacterial Identification {#s2b}
------------------------

Using MALDI-TOF MS, all *K. pneumoniae* strains (100%) were identified with score values \>1.9 using the Bruker Biotyper software.

Antibacterial Susceptibility Testing of *Klebsiella pneumoniae* Isolates {#s2c}
------------------------------------------------------------------------

As shown in [Table 1](#pone-0061428-t001){ref-type="table"}, the overall resistances (i.e., resistant+intermediate percentage (R+I%)) to various antibiotics were as follows: ampicillin, amoxicillin and ticarcillin (100%), amoxicillin/clavulanic acid (55.5%), cefalotin (53.8%), cefoxitin (7.7%), ceftazidime (51.2%), cefotaxime and ceftriaxone (51.0%), gentamicin (48.2%), tobramycin (72.4%), amikacin (26.4%), ciprofloxacin (45.1%), and trimethoprim/sulfamethoxazole (45.7%). All isolates were sensitive to imipenem and colistin. The *K. pneumoniae* strains from Algeria had significantly higher percentages of resistance to antibiotics compared to those from France (*p*\<0.0001). The prevalence of resistance to third generation cephalosporin in Algeria was 88.7% compared with France (26.5%).

10.1371/journal.pone.0061428.t001

###### Origin and repartition of strains used in this study.

![](pone.0061428.t001){#pone-0061428-t001-1}

  Hospital          Department                                                                              Sex/Source                                                                                      Age               Period study        Sample origin                                                                                                                                                                     
  ---------------- ------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------- ----------------------- --------------- -------------------------------------- ----------------------------------- --------------------------------------------------------------------------------------- ---------------
  Annaba                18                                                                             Intensive care unit                                                                                  18                 FemaleMale              810            22 to 62 years24 to 79 years        From March 2009to October 2010                              Tracheal aspirateUrineBlood culture                                1242
  Sidi Bel Abbes        28                                                     Intensive care unitSurgeryInternal medicineNephrologyTraumaEmergency                                                       1472311         FemaleMaleEnvironment       15112           11 to 66 years7 to 75 years        From October 2009to February 2011                 Tracheal aspirateUrineEnvironmentBedsorePusProfound swab                     9322111
  Tlemcen               72                                                        Intensive care unitSurgeryGynecologyNeurologyPediatricsTrauma                                                          48512610         FemaleMaleEnvironment      214011           24 to 70 years7 to 74 years         From August 2008to January 2011                Tracheal aspirateUrineEnvironmentPusRectal swabProfound swab                 2831111181
  Oran                  93                                                             Intensive care unitSurgeryNeurologyPediatricsTrauma                                                                6081096         FemaleMaleEnvironment       36525          1 day to 69 years4 to 73 years        From April 2008to March 2011                   Tracheal aspirateUrineEnvironmentPusRectal swabVaginal swab                  521351391
  Angers               100                                                                             Infectious diseases                                                                                  100                FemaleMale             5644          22 to 97 years1 day to 97 years       From January 2008to March 2011             Tracheal aspirateCatheterUrineBlood culturePusRectal swabVaginal swab             335818396
  Marseille            170       CardiologySurgeryGastroenterologyGeriatric medicineGynecologyInfectious diseasesInternal medicineNephrologyNeurologyPediatricsIntensive care unitTraumaEmergency   7201436614119732437        FemaleMale             9476        6 month to 94 years1 day to 86 years     From January 2009to Jun 2009      Tracheal aspirateCatheterUrineBedsoreBlood culturePusProfound swabSubcutaneous swabND   9110812166117
  Nice                  54                                                                             Infectious diseases                                                                                  54                 FemaleMale             21 33        1 day to 88 years1 day to 88 years    From January 2010to October 2010                                      Blood culturePus                                          2628

Origin and repartition of 535 *Klebsiella pneumoniae* strains isolated between January 2008 and March 2011.

Six resistance phenotypes were found based on susceptibility to beta-lactams ([Table 2](#pone-0061428-t002){ref-type="table"}). These comprised 240 (44.8%) wild-type, 7 (1.3%) inhibitor-resistant TEM penicillinase, 11 (2.0%) high-level penicillinase, 3 (0.6%) cephalosporinase, 240 (44.8%) extended-spectrum beta-lactamase (ESBL), and 34 (6.3%) ESBL associated with cephalosporinase. The difference in antibiotic resistance rate was significant between Algerian and French strains (*p*\<0.0001). Overall, the percentage of non-ESBL-producing strains was higher in France (73.1%) than in Algeria (11.3%), while that of ESBL-producing strains was higher in Algeria (88.6%) compared with France (26.8%).

10.1371/journal.pone.0061428.t002

###### Antibiotic susceptibility testing results of *Klebsiella pneumoniae* strains.

![](pone.0061428.t002){#pone-0061428-t002-2}

             *K. pneumoniae* strains of Algeria (n = 211)   *K. pneumoniae* strains of France (n = 324)   *p* values[\*](#nt102){ref-type="table-fn"}   Total of *K. pneumoniae* strains (n = 535)                                                                                                    
  --------- ---------------------------------------------- --------------------------------------------- --------------------------------------------- -------------------------------------------- ----- ------- ----- ------- ---- ------ ----- ------- ---------- ----- ------- ----- ------ ----- -------
  **AM**                          0                                             0,0                                            0                                           0,0                       211   100,0    0     0,0    0    0,0    324   100,0      --       0     0,0     0    0,0    535   100,0
  **AMX**                         0                                             0,0                                            0                                           0,0                       211   100,0    0     0,0    0    0,0    324   100,0      --       0     0,0     0    0,0    535   100,0
  **AMC**                         27                                           12,8                                           75                                           35,5                      109   51,6    196   67,6    40   13,8   54    18,6    \<0.0001   223   44,5    115   22,9   163   32,5
  **TIC**                         0                                             0,0                                            0                                           0,0                       211   100,0    0     0,0    0    0,0    324   100,0      --       0     0,0     0    0,0    535   100,0
  **CF**                          19                                            9,0                                            0                                           0,0                       192   91,0    228   70,4    2    0,6    94    29,0    \<0.0001   247   46,2     2    0,4    286   53,4
  **FOX**                        182                                           86,2                                           25                                           11,8                       4     1,9    259   97,0    3    1,1     5     1,9       --      441   92,2    28    5,8     9     1,9
  **CTX**                         24                                           11,4                                            0                                           0,0                       187   88,6    238   73,4    4    1,2    82    25,3    \<0.0001   262   49,0     4    0,7    269   50,3
  **CAZ**                         23                                           10,9                                           12                                           5,7                       176   83,4    238   73,4    50   15,4   36    11,1    \<0.0001   261   48,8    62    11,6   212   39,6
  **CRO**                         24                                           11,4                                            0                                           0,0                       187   88,6    238   73,4    4    1,2    82    25,3    \<0.0001   262   49,0     4    0,7    269   50,3
  **IMP**                        211                                           100,0                                           0                                           0,0                        0     0,0    324   100,0   0    0,0     0     0,0       --      535   100,0    0    0,0     0     0,0
  **AN**                         143                                           67,8                                            8                                           3,8                       60    28,4    199   78,3    44   17,3   11     4,3    \<0.0001   342   73,5    52    11,2   71    15,3
  **GN**                          26                                           12,3                                            3                                           1,4                       182   86,2    243   78,9    1    0,3    64    20,8    \<0.0001   269   51,8     4    0,8    246   47,4
  **TM**                          21                                            9,9                                           15                                           7,1                       175   82,9    62    68,9    0    0,0    28    31,1    \<0.0001   83    27,6    15    5,0    203   67,4
  **CIP**                         60                                           28,4                                            8                                           3,8                       143   67,8    224   72,7    2    0,6    81    26,4    \<0.0001   284   54,8    10    1,9    224   43,2
  **CS**                         211                                           100,0                                           0                                           0,0                        0     0,0    324   100,0   0    0,0     0     0,0       --      535   100,0    0    0,0     0     0,0
  **SXT**                         57                                           27,0                                            7                                           3,3                       147   69,7    223   73,1    2    0,6    80    26,2    \<0.0001   280   54,3     9    1,7    227   44,0

the *p* values compare the percentage of resistance and sensitivity between Algerian and French strains,

**S**: Sensitive, **I** : Intermediate, **R** : Resistant, **AM**: Ampicillin, **AMX**: Amoxicillin, **AMC**: Amoxicillin/clavulanic acid, **TIC**: Ticarcillin, **CF**: Cefalotin, **FOX**: Cefoxitin, **CAZ**: Ceftazidime, **CTX**: Cefotaxime, **CRO**: Ceftriaxone, **IMP**: Imipenem, **GN**: Gentamicin, **AN**: Amikacin, **TM**: Tobramycin, **CIP**: Ciprofloxacin, **SXT**: Trimethoprim/Sulfamethoxazole, **CS**: Colistin.

Data Mining Analysis of *Klebsiella pneumoniae* MSP Dendrogram {#s2d}
--------------------------------------------------------------

The MSP dendrogram revealed five distinct clusters according to an arbitrary cut-off at the distance level of 500 ([Figure 1](#pone-0061428-g001){ref-type="fig"}). Data mining analysis of the five clusters using PASW 17.0 software showed that *K. pneumoniae* strains isolated in Algerian hospitals (Tlemcen, Sidi Bel Abbes, Oran, Annaba) were significantly associated with respiratory tract infections and ESBL phenotype in the fifth cluster (*p*\<0.0001), whereas *K. pneumoniae* strains isolated in Marseille hospitals were significantly associated with urinary tract infections and wild type phenotype in the first, the second and the fourth clusters (*p*\<0.0001). *K. pneumoniae* strains isolated in Angers hospitals were associated with urinary tract infections and wild type phenotype in the fourth cluster (*p*\<0.0001). Conversely, *K. pneumoniae* strains isolated in Nice hospital were associated with blood cultures and pus samples and wild type phenotype in the third cluster (*p*\<0.0001) ([Table 3](#pone-0061428-t003){ref-type="table"}). All the details of the distribution of *K. pneumoniae* strains into the five clusters according to the dendrogram are given in supplementary [Table S1](#pone.0061428.s001){ref-type="supplementary-material"}. Interestingly, clustering the strains according to the arbitrary distance levels of 180 and 100 significantly clustered strains from the same hospital into the same cluster. At the distance level of 180, 34 distinct clusters were identified, and at the distance level of 100, 52 distinct clusters were identified ([Table S2](#pone.0061428.s002){ref-type="supplementary-material"}). For example, at the distance level of 100, one cluster containing 15 strains showed that all of them were from Marseille hospital, a second cluster contained three strains (all from Nice hospital), and a third cluster contained ten strains (eight out of ten were from Angers hospital (*p*\<0.0001)).

![Geographic location of hospitals implicated in this study.\
1: Tlemcen, 2: Sidi Bel Abbes, 3: Oran, 4: Annaba, 5: Marseille, 6: Nice, 7: Angers.](pone.0061428.g001){#pone-0061428-g001}

10.1371/journal.pone.0061428.t003

###### Antibacterial resistance phenotypes of *Klebsiella pneumoniae* strains.
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                         Tlemcen(%)   Sidi BelAbbes (%)    Oran(%)    Annaba(%)    TotalAlgeria (%)   Angers(%)    Nice(%)    Marseille(%)   TotalFrance (%)    Total(%)
  --------------------- ------------ ------------------- ----------- ------------ ------------------ ----------- ----------- -------------- ----------------- ------------
  **ESBL**               58 (80,5)        21 (75,0)       62 (66,7)   18 (100,0)      159 (75,3)      24 (24,0)   7 (13,0)     50 (29,4)        81 (25,0)      240 (44,8)
  **ESBL+Case**           9 (12,5)        3 (10,7)        16 (17,2)    0 (0,0)        28 (13,3)        6 (6,0)     0 (0,0)      0 (0,0)          6 (1,8)        34 (6,3)
  **Case**                1 (1,4)          0 (0,0)         0 (0,0)     0 (0,0)         1 (0,5)         2 (2,0)     0 (0,0)      0 (0,0)          2 (0,6)        3 (0,6)
  **Pase High Level**     1 (1,4)          1 (3,6)         2 (2,1)     0 (0,0)         4 (1,9)         0 (0,0)    7 (13,0)      0 (0,0)          7 (2,2)        11 (2,0)
  **Pase IRT**            0 (0,0)          2 (7,1)         0 (0,0)     0 (0,0)         2 (0,9)         2 (2,0)     1 (1,8)      2 (1,2)          5 (1,5)        7 (1,3)
  **Wild Type**           3 (4.2)          1 (3,6)        13 (14,0)    0 (0,0)         17 (8,0)       66 (66,0)   39 (72,2)    118 (69,4)      223 (68,8)      240 (44,8)
  **Total**                  72              28              93           18             211             100         54           170              324            535

ESBL: Extended-spectrum beta-lactamase, Case: Cephalosporinase, ESBL+Case: Extended-spectrum beta-lactamase associated to Cephalosporinase phenotype, Pase: Penicillinase, Pase IRT: inhibitor-resistant TEM penicillinase.

The monthly distribution of *K. pneumoniae* strains for the January 2008 - March 2011 period was determined by PASW 17.0 software according to clusters. Strains from Angers and Algerian hospitals were significantly correlated with winter (January-March) (*p*\<0.0001), whereas, strains from Marseille hospital were associated with spring (April-June) (*p*\<0.0001). No seasonal variation was associated with strains from Nice hospital.

Multilocus Sequence Typing {#s2e}
--------------------------

The MLST allelic profile of all strains distributed in the five clusters is presented in [Table 4](#pone-0061428-t004){ref-type="table"}. From the 28 tested strains, we found 24 different sequence types (ST) ([Figure 2](#pone-0061428-g002){ref-type="fig"}). No relationship was observed between ST and the clinical and epidemiological data.

![Mean spectra projection (MSP) dendrogram of *Klebsiella pneumoniae* strains generated by BIOTYPER software (version 2; Bruker Daltonics).\
ESBL: Extended-spectrum beta-lactamase, WT: wild type.](pone.0061428.g002){#pone-0061428-g002}

10.1371/journal.pone.0061428.t004

###### Data mining analysis of *Klebsiella pneumoniae* MSP dendrogram.

![](pone.0061428.t004){#pone-0061428-t004-4}

  Clusters (No)    Geographic location(No)   Type of samples (No)   Antibiotic resistancePhenotype (No)   Association between the antibioticresistance phenotype and typeof samples(No)   Seasonality(No)                                                                                    
  --------------- ------------------------- ---------------------- ------------------------------------- ------------------------------------------------------------------------------- ----------------- ------ ----- ---------------------------------- ------ -------------------------- ---------
  **C1+ C2**                 23                   Marseille                         22                                                        Urine                                             14           WT    19              Urine and WT              13             Spring              22
  **C3**                     65                      Nice                           47                                                  Blood culturePus                                       2225          WT    35    Blood culture and WTUrine and WT   1718   SpringSummerAutumnWinter   1017146
  **C4**                     215                  Marseille                         117                                                       Urine                                             74           WT    79              Urine and WT              56             Spring              62
                                                    Angers                          54                                                        Urine                                             33           WT    34              Urine and WT              19             Winter              36
  **C5**                     232                   Algeria                          166                                                 Tracheal aspirate                                       82          ESBL   149      Tracheal aspirate and ESBL       73             Winter              70

WT: wild type phenotype, ESBL: Extended Spectrum Beta-lactamase**.** No represents the number of strains that correspond to the significant character according to data mining analysis.

Discussion {#s3}
==========

*K. pneumoniae* is an important pathogen with a complex pan-genome responsible for serious nosocomial infections, especially in intensive care units (ICUs) and in wards for surgery, emergency, neurology, pediatrics, and neonatology [@pone.0061428-Podschun1]. More concerning has been the emergence and increase in the isolation rate of ESBL-producing *K. pneumoniae* worldwide [@pone.0061428-Khan1], which frequently possess resistance factors to other classes of antibiotics, notably aminoglycosides, fluoroquinolones and trimethoprim/sulfamethoxazole [@pone.0061428-Briales1]. In our study, we confirmed that there is an increase in the number of multidrug-resistant *K. pneumoniae* strains with a considerable variation between the two countries studied. The antibiotic resistance rate in France (26.8%) was lower than that in Algeria (88.6%). In comparing our results with those of the Mystic study (1997--2003) [@pone.0061428-Turner1] and another surveillance trial study (2004--2009) [@pone.0061428-Bertrand1], we notice a worldwide north-south gradient evolution of ESBL production rate in *K. pneumoniae* strains with 12.3--12.8% in North America, 16.7% in Northern Europe, 24.4% in Southern Europe, 33.8% in the Middle East, 28.2--35.6% in Asia-Pacific, 45.5--51.9% in South America and 54.9% in Africa.

The high infection occurrence of *K. pneumoniae*, both ESBL-producing and non-producing strains, in Algerian and French hospitals pushed us to examine the epidemiology of these strains, which are considered to have a complex pan-genome containing plastic genome repertoires that differentiate strains according to their geographical locations, pathotypes, ecotypes and resistance phenotypes [@pone.0061428-Diene1]. MALDI-TOF MS was successfully used as a tool for biotyping because we found specific clusters that were significantly associated with particular phenotypes from different clinical and geographical sources and from different seasons. This result is seemingly supported by Trevino et al., with a series of only 13 clinical isolates of *K. pneumoniae* [@pone.0061428-Trevino1]. By increasing the number of strains collected, our dendrogram became more refined, not only by country but also by hospital. This result could be of clinical importance for unknown pathogenic isolates, whose geographical sources could be detected rapidly using MALDI-TOF MS.

It is recognized that the distribution of bacteria may be related to geographical patterns, such as climatic zones and movement of human populations, and can provide information about pathogen evolution and transmission [@pone.0061428-Leimkugel1], [@pone.0061428-Vesaratchavest1]. The spatial distribution of bacterial pathogens can be considered at different levels; in a hospital setting, this may indicate nosocomial transmission, but in a community setting, the simultaneous appearance of an identical phenotype in widely dispersed locations may be a warning of an outbreak [@pone.0061428-Baker1]. Our data also suggested that rates of *K. pneumoniae* infections varied seasonally and were significantly associated with periods of isolation that were due to changes in temperature and humidity. Several characteristics of this species that were previously described support our findings, which show that temperature and dew point were both linearly predictive of increasing rates of *K. pneumoniae* clinical isolates [@pone.0061428-Anderson1], [@pone.0061428-Okada1]. Furthermore, most of the MALDI-TOF MS spectra are composed of well-conserved proteins with housekeeping functions that are minimally affected by environmental conditions and thus are considered to be optimal for the proteomic typing of bacteria, which is considerably different from genetic typing [@pone.0061428-Croxatto1], [@pone.0061428-Ryzhov1].

By comparing the clusters obtained from the MSP dendrogram ([Figure 1](#pone-0061428-g001){ref-type="fig"}) with the ST distribution in the minimal spanning tree (MST) of *K. pneumoniae* strains ([Figure 2](#pone-0061428-g002){ref-type="fig"}), we noted that no correlation was observed for these two types of analysis. Moreover, no relationship was observed between ST, clinical and epidemiological data. These results suggest that the two approaches, comprising the MSP and MLST analyses, highlight two different bacterial aspects. Indeed, MLST analysis based on the conserved bacterial genes (the house-keeping genes) classifies bacteria according to their core genome, which represents less than 10% of the genome [@pone.0061428-Dieckmann1], while 90% of the genome is composed of "accessory genes" (mobile genetic elements) that can be lost or acquired by lateral gene transfer (LGT), and that is mainly responsible for the bacterial phenotype [@pone.0061428-Diene1], [@pone.0061428-Lukjancenko1]. Therefore, this core genome does not represent the majority of expressed proteins, in contrast to the MSP dendrogram analysis, which is based on the functional and expressed proteins of whole cells that is more representative of the global phenotype [@pone.0061428-Yip1]. Therefore, these two approaches could be complementary to the extent that the MST approach, based on the analysis of the core genome, allows us to classify bacteria according to their conserved genes independent of their "accessory genes," which can affect phenotypes and bacterial classification.

Many researchers have used molecular methods, particularly PFGE and MLST, to distinguish *K. pneumoniae* clinical isolates in order to understand transmission patterns and to aid in the management of these infections [@pone.0061428-Diancourt1]. In 2008, a comparative study between these two methods found that PFGE is appropriate to discriminate among epidemiologically unrelated strains and appears more suitable for short-term epidemiology, while MLST is appropriate for strain phylogeny and large-scale epidemiology [@pone.0061428-Vimont1]. Furthermore, these molecular methods are costly and time-consuming to obtain results and introduce delays when attempting to limit the spread of *K. pneumoniae* clones [@pone.0061428-Fujinami1]. For instance, only a few hours are required to obtain results by MALDI-TOF MS, whereas several days are necessary to collect MLST data [@pone.0061428-Ilina1]. In addition, the cost of MALDI-TOF MS instrumentation is comparable to that of a sequencing machine, but running costs and consumables are considerably lower than for these methods [@pone.0061428-Barbuddhe2]. Barbuddhe et al. have used MALDI-TOF MS to accurately identify different *Listeria* species and correctly classified all *L. monocytogenes* serotypes in agreement with PFGE [@pone.0061428-Barbuddhe2], and recently Wang et al. identified and classified *Streptococcus pyogenes* into clusters with MALDI-TOF MS [@pone.0061428-Wang1].

Thus, MALDI-TOF MS combined with a statistical classification strategy is appropriate for studies of local epidemiology and global population structure when compared to a local database from clinical strains. It is a powerful epidemiological method and is sufficiently reproducible and sensitive enough to rapidly survey the evolution of existing or emerging phenotypes with reduced financial and human costs [@pone.0061428-Drancourt1].

Conclusion {#s3a}
----------

We believe that our preliminary results should be expanded and confirmed with more strains obtained from different countries. To the best of our knowledge, this is the first study that analyzes the epidemiology of a large series of *K. pneumoniae* clinical isolates using MALDI-TOF MS application. We suggest the creation of a local database that is updated regularly to survey for the presence of abnormal phenotypes at the strain level. If a particular phenotype is detected, a real time genome sequencing approach could then be performed to investigate the origin and specific features of the strain. We believe that this methodology could be used routinely in clinical microbiology laboratories as a surveillance tool for hospital epidemiology studies to prevent outbreaks and dissemination of pathogens in hospital settings.

Materials and Methods {#s4}
=====================

Bacterial Strains {#s4a}
-----------------

A total of 535 non redundant clinical strains of *K. pneumoniae*, isolated from different clinical samples, were collected during a period of 39 weeks, between January 2008 and March 2011. All of these were collected from hospitals in France and Algeria ([Figure 3](#pone-0061428-g003){ref-type="fig"}): Marseille hospitals, France (n = 170 strains); Angers hospital, France (n = 100 strains); Nice hospital, France (n = 54 strains), Tlemcen hospital, Algeria (n = 73 strains); Oran hospital, Algeria (n = 92 strains); Sidi Bel Abbes hospital, Algeria (n = 28 strains) and Annaba hospital, Algeria (n = 18 strains). The clinical sources of the different strains are noted in [Table 5](#pone-0061428-t005){ref-type="table"}.

![Minimal spanning tree (MST) of *K. pneumoniae* isolates, showing relationships between STs, compared with clusters obtained from the dendrogram generated by BIOTYPER software.](pone.0061428.g003){#pone-0061428-g003}

10.1371/journal.pone.0061428.t005

###### MLST allelic profile of *Klebsiella pneumoniae* clinical isolates distributed in the five clusters.
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  Clusters    Isolates      Hospitals        Sample origin     Antibiotic resistance phenotype   gapA   infB   mdh   pgi   phoE   rpoB   tonB      ST
  ---------- ----------- ---------------- ------------------- --------------------------------- ------ ------ ----- ----- ------ ------ ------ -----------
  **C1**       KpM 44       Marseille            Urine                       WT                   2      1      2    17     27     1      39    **ST107**
               KpM 71       Marseille             Pus                        WT                   4      1      7     1     9      1      12    **ST10**
  **C2**      KpnA1211        Annaba       Tracheal aspirate                ESBL                  3      3      1     1     1      1      4     **ST11**
               KpM 29       Marseille        Blood culture                  ESBL                  2      6      1     5     4      1      6     **ST101**
  **C3**        29 Kp          Nice               Pus                        WT                   2      2      1    47     1      4      43    **ST279**
               KpM 154      Marseille            Urine                       WT                   2      1      5     1     17     4      42    **ST111**
              KpnA 1323       Annaba       Tracheal aspirate                ESBL                  2      1      1     1     9      1      20    **ST704**
                16 KP          Nice               Pus                        WT                   2      1      5     1     17     4      42    **ST111**
                16 KH          Nice          Blood culture                   WT                   14     1      2     1     21     1      23    **ST113**
                KpA4          Angers         Vaginal swab                    WT                   16     24    21    53     47     17     67    **ST360**
                KpA63         Angers       Tracheal aspirate                 WT                   9      4      2     1     1      1      27    **ST86**
                Kpn8           Oran           Rectal swab              Pase High Level            2      1      1    37     10     1      86    **ST290**
                14 KP          Nice               Pus                        WT                   4      5      1    29     1      4      42    **ST610**
                10 KP          Nice               Pus                       ESBL                  2      1      5     1     17     4      42    **ST111**
  **C4**        Kpn9           Oran        Tracheal aspirate                 WT                   2      3      1     1     2      1      43    **ST104**
               KpM 166      Marseille             ND                        ESBL                  1      1      1     1     1      1      1     **ST15**
               KpM 161      Marseille             ND                        ESBL                  17     19    39    39     51     72     72    **ST196**
                KpA86         Angers             Urine                       WT                   3      1      2     1     1      1      4     **ST134**
                KpA75         Angers         Blood culture                   WT                   2      6      1     5     4      1      6     **ST101**
                Okp46          Oran        Tracheal aspirate              ESBL+Case               2      1      2     1     10     1      19    **ST35**
                Okp45          Oran        Tracheal aspirate                ESBL                  1      6      1     1     1      1      1     **ST14**
                Kp98         Tlemcen          Rectal swab                   ESBL                  2      1      1     1     10     4      13    **ST25**
  **C5**       KpM 170      Marseille        Blood culture                  ESBL                  2      1      2     1     10     1      19    **ST35**
                Kp90         Tlemcen              Pus                       ESBL                  2      10    13     1     12     1     186    **ST915**
                Skp25     Sidi Bel Abbes          Pus                       ESBL                  2      1      1     1     9      1      93    **ST323**
                Skp22     Sidi Bel Abbes        Bedsore                     ESBL                  2      1     65     2     5      1      36    **ST420**
              KpnA 932        Annaba       Tracheal aspirate                ESBL                  2      9      2     1     13     1      16    **ST37**
              KpnA 576        Annaba             Urine                      ESBL                  4      1      1     1     1      5      6      **ST8**

ESBL: Extended-spectrum beta-lactamase, ESBL+Case: Extended-spectrum beta-lactamase associated to Cephalosporinase phenotype, Pase: Penicillinase phenotype, WT: Wild Type phenotype.

*Klebsiella pneumoniae* Identification using MALDI-TOF MS {#s4b}
---------------------------------------------------------

Isolates were plated on Trypticase Soy Agar (BioMerieux) and incubated for 24 h at 37°C. One single colony from each isolate was deposited on a MALDI-TOF MTP 384 target plate (Bruker Daltonics, Bremen, Germany) in four replicates to minimize random effects. Two microliters of matrix solution (saturated α-cyano-4-hydroxycinnamic acid, 50% acetonitrile, 2.5% trifluoroacetic acid) were then added and allowed to co-crystallize with the sample. Analysis was performed in a MALDI-TOF MS spectrometer (337 nm) (Autoflex; Bruker Daltonics) with FLEX control software (Bruker Daltonics). Ions were accelerated in the positive ion mode with an accelerating voltage of 20 kV. The pulsed extraction of ions was optimized for 1000 Da. The software employed, Bruker Biotyper 2.0 (Bruker Daltonics), automatically acquired spectra with fuzzy control of the laser intensity and analyzed them by standard pattern matching against the spectra of 2881 species used as reference data. After comparing the unknown spectra with all reference spectra in the database, the log scores were ranked. Values of \>1.9 were required for secure identification at the species level, and values between 1.9 and 1.7 were required for secure identification at the genus level.

Clustering of MALDI-TOF Spectra {#s4c}
-------------------------------

A consensus spectrum was produced, and an MSP dendrogram was constructed using the correlation distance measure with the average linkage algorithm setting of the Biotyper 2.0 software. Clusters were then detailed and analyzed according to arbitrary distance levels at 500, 180 and 100.

Antibiotic Susceptibility and Synergy Testing {#s4d}
---------------------------------------------

Antibiotic susceptibility testing was performed using the disk diffusion method on Mueller-Hinton medium as per the guidelines of the French Society of Microbiology ([www.sfm.asso.fr](http://www.sfm.asso.fr)). *E. coli* ATCC 25922 was used as a quality control strain. The antimicrobial disks tested were as follows: ampicillin (10 µg), amoxicillin (25 µg), amoxicillin/clavulanic acid (20/10 µg), ticarcillin (75 µg), cefalotin (30 µg), cefoxitin (30 µg), ceftazidime (30 µg), cefotaxime (30 µg), ceftriaxone (30 µg), imipenem (10 µg), gentamicin (15 µg), amikacin (30 µg), tobramycin (10 µg), ciprofloxacin (5 µg), trimethoprim/sulfamethoxazole (1,25/23,75 µg), and colistin (50 µg). ESBL production was detected using the method of combined antibiotic disks as previously described [@pone.0061428-Jarlier1].

Antibiotic Resistance Phenotypic Classification of *K. pneumoniae* Strains based on Beta-Lactamine Compounds {#s4e}
------------------------------------------------------------------------------------------------------------

We considered a wild type phenotype as a strain that confer resistance to aminopenicillins, carboxypenicillins and to ureidopenicillins. The high level penicillinase phenotype was presented by a high penicillinase activity responsible for resistance to aminopenicillins and their inhibitors, to carboxypenicillins, to ureidopenicillins, and to first generation cephalosporins (1 GC). The inhibitor-resistant TEM penicillinase phenotype included resistance to aminopenicillins, carboxypenicillins, and ureidopenicillins. It was distinguished by resistance to aminopenicillins and carbocxypenicillins associated to the beta-lactam inhibitors. 1 GC generally retain their activity. The cephalosporinase phenotype corresponded to a marked resistance to penicillins, 1 GC, 2 GC, and to at least one 3 GC. The extended spectrum B-lactamase phenotype includes resistance to penicillins and cephalosporins except cephamycins. The resistance to 3 GC and 4 GC was more or less pronounced depending on the enzymes and the strains.

Statistical Analysis {#s4f}
--------------------

Clinical and epidemiological data were recorded in an Excel file (Microsoft, Redmond, WA, USA), including the clustering obtained using the MSP dendrogram generated by the Biotyper software (version 2; Bruker Daltonics), and were analyzed using PASW Statistics software version 17.0 (SPSS Inc., Chicago, IL, USA). Dependent variable series were analyzed using Expert Modeler, which automatically generates the best-fitting model. The chi-square analysis was used also to compare proportions using the same software, and *P* values \<0.05 were considered to be statistically significant. Statistical analyses were conducted using Epi Info version 6 (Centers for Disease Control and Prevention, Atlanta, GA, USA).

Multilocus Sequence Typing {#s4g}
--------------------------

Randomly, 28 strains distributed in the five clusters were selected to perform the full MLST as described previously using seven housekeeping genes, including *gapA*, *infB*, *mdh*, *pgi*, *phoE*, *rpoB* and *tonB* [@pone.0061428-Diancourt1]. The MLST database for *K. pneumoniae* can be found at <http://www.pasteur.fr>. Based on the allelic profiles, the evolutionary relationship between isolates was assessed by the minimal spanning tree (MST) algorithm in Bionumerics (Applied Maths, NV St-Martens-Latem, Belgium). A stringent definition of 6/7 shared alleles was used to define clonal complexes (single locus variants only).

Supporting Information {#s5}
======================
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Distribution of *Klebsiella pneumoniae* strains according to the dendrogram generated by BIOTYPER software (version 2, Bruker Daltonics) at the distance level of 500.
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Click here for additional data file.

###### 

Comparison of the clusters obtained according to different cut-offs at 500, 180 and 100 of the dendrogram generated by BIOTYPER software (version 2, Bruker Daltonics).

(DOCX)

###### 

Click here for additional data file.
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